They are running out of words to make up for medication trade names cause what the fuck is tryngolza
July 28, 2026 at 11:30 PM
They are running out of words to make up for medication trade names cause what the fuck is tryngolza
🎯First-in-class
US FDA has approved Tryngolza (olezarsen), used with diet, to reduce triglycerides (TG) in adults with familial chylomicronemia syndrome (FCS).
www.fda.gov/drugs/news-e...
US FDA has approved Tryngolza (olezarsen), used with diet, to reduce triglycerides (TG) in adults with familial chylomicronemia syndrome (FCS).
www.fda.gov/drugs/news-e...
FDA approves Tryngolza (olezarsen)
FDA has approved Tryngolza (olezarsen), used with diet, to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).
www.fda.gov
December 20, 2024 at 12:35 AM
🎯First-in-class
US FDA has approved Tryngolza (olezarsen), used with diet, to reduce triglycerides (TG) in adults with familial chylomicronemia syndrome (FCS).
www.fda.gov/drugs/news-e...
US FDA has approved Tryngolza (olezarsen), used with diet, to reduce triglycerides (TG) in adults with familial chylomicronemia syndrome (FCS).
www.fda.gov/drugs/news-e...
Patients in #England and #Wales with #raredisease #familialchylomicronaemiasyndrome (FCS) will soon have a new treatment option, after #Sobi's #Tryngolza was recommended for #NHS use by #NICE.
pharmaphorum.com/news/nice-ba...
pharmaphorum.com/news/nice-ba...
NICE backs Sobi's Tryngolza for rare disease FCS
Patients in England and Wales with familial chylomicronaemia syndrome will soon have a new treatment option, as NICE backs Sobi's Tryngolza.
pharmaphorum.com
October 1, 2026 at 1:47 PM
Patients in #England and #Wales with #raredisease #familialchylomicronaemiasyndrome (FCS) will soon have a new treatment option, after #Sobi's #Tryngolza was recommended for #NHS use by #NICE.
pharmaphorum.com/news/nice-ba...
pharmaphorum.com/news/nice-ba...
In Brief: The @fda.gov approves Ionis Pharmaceuticals’ triglyceride-lowering rare disease drug #Tryngolza www.nature.com/articles/s41...
rdcu.be/d6V0J
rdcu.be/d6V0J
Ionis wins FDA nod for triglyceride-lowering rare disease drug - Nature Biotechnology
Nature Biotechnology - Ionis wins FDA nod for triglyceride-lowering rare disease drug
www.nature.com
January 20, 2025 at 5:13 PM
In Brief: The @fda.gov approves Ionis Pharmaceuticals’ triglyceride-lowering rare disease drug #Tryngolza www.nature.com/articles/s41...
rdcu.be/d6V0J
rdcu.be/d6V0J
It's Trivia Tuesday! This question is from our article Olezarsen (Tryngolza) for Severe Hypertriglyceridemia https://bit.ly/4xOEqBl
Answer: d
Increases in fasting glucose levels and A1C have also been reported; these were most pronounced in patients with preexisting diabetes.
Answer: d
Increases in fasting glucose levels and A1C have also been reported; these were most pronounced in patients with preexisting diabetes.
September 29, 2026 at 7:09 PM
It's Trivia Tuesday! This question is from our article Olezarsen (Tryngolza) for Severe Hypertriglyceridemia https://bit.ly/4xOEqBl
Answer: d
Increases in fasting glucose levels and A1C have also been reported; these were most pronounced in patients with preexisting diabetes.
Answer: d
Increases in fasting glucose levels and A1C have also been reported; these were most pronounced in patients with preexisting diabetes.
Big news in lipidology!🎉 The FDA has approved TRYNGOLZA™ (olezarsen) 80mg injection — the 1st treatment for adults with familial chylomicronemia syndrome (FCS) to lower triglycerides, alongside diet.
Read the press release: ir.ionis.com/news-release... #LipidScience
Read the press release: ir.ionis.com/news-release... #LipidScience
ir.ionis.com
December 20, 2024 at 4:42 PM
Big news in lipidology!🎉 The FDA has approved TRYNGOLZA™ (olezarsen) 80mg injection — the 1st treatment for adults with familial chylomicronemia syndrome (FCS) to lower triglycerides, alongside diet.
Read the press release: ir.ionis.com/news-release... #LipidScience
Read the press release: ir.ionis.com/news-release... #LipidScience
Groundbreaking Results Demonstrate Tryngolza®'s Power Against Acute Pancreatitis and Hypertriglyceridemia#USA#Stockholm#Olezarsen#Sobi®#Tryngolza®
Groundbreaking Results Demonstrate Tryngolza®'s Power Against Acute Pancreatitis and Hypertriglyceridemia
A new analysis marks a significant breakthrough in treating severe hypertriglyceridemia, as Tryngolza® showcases exceptional efficacy in preventing acute pancreatitis and lowering triglycerides.
third-news.com
May 26, 2026 at 3:21 PM
Groundbreaking Results Demonstrate Tryngolza®'s Power Against Acute Pancreatitis and Hypertriglyceridemia#USA#Stockholm#Olezarsen#Sobi®#Tryngolza®
Recent Research Highlights the Efficacy of Tryngolza® in Preventing Acute Pancreatitis Events#Sweden#Stockholm#Sobi#Olezarsen#Tryngolza
Recent Research Highlights the Efficacy of Tryngolza® in Preventing Acute Pancreatitis Events
A new study reveals Tryngolza® (olezarsen) significantly lowers the risk of acute pancreatitis and triglyceride levels in severe hypertriglyceridemia patients, reducing pancreatitis by 85%.
third-news.com
May 26, 2026 at 3:19 PM
Recent Research Highlights the Efficacy of Tryngolza® in Preventing Acute Pancreatitis Events#Sweden#Stockholm#Sobi#Olezarsen#Tryngolza
Ionis Pharmaceuticals sued biotech rival Arrowhead Pharmaceuticals for patent infringement in California federal court over Arrowhead's planned competitor to Ionis' drug Tryngolza @blakebrittain.bsky.social reut.rs/4mSOUuU
Ionis, Arrowhead file dueling patent lawsuits over genetic-disorder drug
Ionis Pharmaceuticals sued biotech rival Arrowhead Pharmaceuticals for patent infringement in California federal court on Thursday over Arrowhead's planned competitor to Ionis' drug Tryngolza.
reut.rs
September 12, 2025 at 1:19 AM
Ionis Pharmaceuticals sued biotech rival Arrowhead Pharmaceuticals for patent infringement in California federal court over Arrowhead's planned competitor to Ionis' drug Tryngolza @blakebrittain.bsky.social reut.rs/4mSOUuU
Ionis Pharmaceuticals sued biotech rival Arrowhead Pharmaceuticals for patent infringement in California federal court on Thursday over Arrowhead's planned competitor to Ionis' drug Tryngolza.
Ionis, Arrowhead file dueling patent lawsuits over genetic-disorder drug
Ionis Pharmaceuticals sued biotech rival Arrowhead Pharmaceuticals for patent infringement in California federal court on Thursday over Arrowhead's planned competitor to Ionis' drug Tryngolza.
reut.rs
September 11, 2025 at 8:10 PM
Ionis Pharmaceuticals sued biotech rival Arrowhead Pharmaceuticals for patent infringement in California federal court on Thursday over Arrowhead's planned competitor to Ionis' drug Tryngolza.
$IONS +3.15% (+4.56% Wed.) [Morgan Stanley upgraded Ionis Pharmaceuticals to Overweight from Equal Weight with a price target of $62. "The company showed strong early trends for TRYNGOLZA and has multiple catalysts ahead."]
July 31, 2025 at 9:53 AM
$IONS +3.15% (+4.56% Wed.) [Morgan Stanley upgraded Ionis Pharmaceuticals to Overweight from Equal Weight with a price target of $62. "The company showed strong early trends for TRYNGOLZA and has multiple catalysts ahead."]
The FDA approved Tryngolza (olezarsen) for adults with severe hypertriglyceridemia. It may lower triglycerides and reduce pancreatitis risk, but it is not a blood-glucose treatment. Read: https://livingdiabetes.com/tryngolza-olezarsen-severe-hypertriglyceridemia-diabetes/ #Diabetes #HeartHealth
July 20, 2026 at 4:45 PM
The FDA approved Tryngolza (olezarsen) for adults with severe hypertriglyceridemia. It may lower triglycerides and reduce pancreatitis risk, but it is not a blood-glucose treatment. Read: https://livingdiabetes.com/tryngolza-olezarsen-severe-hypertriglyceridemia-diabetes/ #Diabetes #HeartHealth
🚨 JUST IN: $IONS
FDA approves Ionis' TRYNGOLZA for severe hypertriglyceridemia, cuts pancreatitis risk 91%
#SEC #stocks #investing #IONS #Regulatory
🔗 secwatch.observer
FDA approves Ionis' TRYNGOLZA for severe hypertriglyceridemia, cuts pancreatitis risk 91%
#SEC #stocks #investing #IONS #Regulatory
🔗 secwatch.observer
June 24, 2026 at 8:16 PM
🚨 JUST IN: $IONS
FDA approves Ionis' TRYNGOLZA for severe hypertriglyceridemia, cuts pancreatitis risk 91%
#SEC #stocks #investing #IONS #Regulatory
🔗 secwatch.observer
FDA approves Ionis' TRYNGOLZA for severe hypertriglyceridemia, cuts pancreatitis risk 91%
#SEC #stocks #investing #IONS #Regulatory
🔗 secwatch.observer
Pretty sure I saw a Medecins Sans Frontieres fundraiser ad highlighting their work with refugees in Tryngolza.
July 28, 2026 at 11:40 PM
Pretty sure I saw a Medecins Sans Frontieres fundraiser ad highlighting their work with refugees in Tryngolza.
#IONS TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet
https://www.stocktitan.net/news/IONS/tryngolzatm-olezarsen-approved-in-u-s-as-first-ever-treatment-for-he13b32n7voj.html
https://www.stocktitan.net/news/IONS/tryngolzatm-olezarsen-approved-in-u-s-as-first-ever-treatment-for-he13b32n7voj.html
Ionis Secures Historic FDA Approval for First-Ever FCS Treatment, TRYNGOLZA Shows 57% Triglyceride Reduction
Breakthrough FDA approval positions Ionis in rare disease market with TRYNGOLZA, demonstrating remarkable efficacy in FCS treatment with 57% triglyceride reduction and significant pancreatitis prevention.
www.stocktitan.net
December 19, 2024 at 11:29 PM
#IONS TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet
https://www.stocktitan.net/news/IONS/tryngolzatm-olezarsen-approved-in-u-s-as-first-ever-treatment-for-he13b32n7voj.html
https://www.stocktitan.net/news/IONS/tryngolzatm-olezarsen-approved-in-u-s-as-first-ever-treatment-for-he13b32n7voj.html
This work is also quite timely with news from Ionis about their latest FDA approval for an ASO-based drug (Tryngolza) to treat a rare metabolic disorder.
www.reuters.com/business/hea...
www.reuters.com/business/hea...
US FDA approves Ionis Pharma's genetic disorder drug
The U.S. Food and Drug Administration has approved Ionis Pharmaceuticals' drug to treat a rare genetic disorder, making it the company's first wholly-owned drug, the health regulator's website showed on Thursday.
www.reuters.com
December 21, 2024 at 4:29 PM
This work is also quite timely with news from Ionis about their latest FDA approval for an ASO-based drug (Tryngolza) to treat a rare metabolic disorder.
www.reuters.com/business/hea...
www.reuters.com/business/hea...
The FDA approved olezarsen (Tryngolza) to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia, the agency announced on Wednesday.
https://www.medpagetoday.com/cardiology/dyslipidemia/121914
https://www.medpagetoday.com/cardiology/dyslipidemia/121914
Severe Hypertriglyceridemia Drug Approved to Reduce Triglycerides, Pancreatitis Risk
Olezarsen indicated as an adjunct to diet
www.medpagetoday.com
June 24, 2026 at 8:58 PM
The FDA approved olezarsen (Tryngolza) to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia, the agency announced on Wednesday.
https://www.medpagetoday.com/cardiology/dyslipidemia/121914
https://www.medpagetoday.com/cardiology/dyslipidemia/121914
#biotecnología hoy:
🧬 $APTO Extensión Nasdaq aprobada
🩺 $HUMA FDA aprueba SYMVESS
⚖️ $NVO CagriSema: -22.7%
₿ $QNTM Compra $1M en cripto
🩹 $IONS TRYNGOLZA aprobado FDA
🧑⚕️ $RCEL 510k para Cohealyx
¡Sigue para más!
#Salud #biotech #stocks #mercados
www.biopharmcatalyst.com/news/2024/ap...
🧬 $APTO Extensión Nasdaq aprobada
🩺 $HUMA FDA aprueba SYMVESS
⚖️ $NVO CagriSema: -22.7%
₿ $QNTM Compra $1M en cripto
🩹 $IONS TRYNGOLZA aprobado FDA
🧑⚕️ $RCEL 510k para Cohealyx
¡Sigue para más!
#Salud #biotech #stocks #mercados
www.biopharmcatalyst.com/news/2024/ap...
Biotech catalyst calendars and drug pipelines • BioPharmCatalyst
Profit on the stock market by investing in biotech stocks
www.biopharmcatalyst.com
December 20, 2024 at 2:38 PM
#biotecnología hoy:
🧬 $APTO Extensión Nasdaq aprobada
🩺 $HUMA FDA aprueba SYMVESS
⚖️ $NVO CagriSema: -22.7%
₿ $QNTM Compra $1M en cripto
🩹 $IONS TRYNGOLZA aprobado FDA
🧑⚕️ $RCEL 510k para Cohealyx
¡Sigue para más!
#Salud #biotech #stocks #mercados
www.biopharmcatalyst.com/news/2024/ap...
🧬 $APTO Extensión Nasdaq aprobada
🩺 $HUMA FDA aprueba SYMVESS
⚖️ $NVO CagriSema: -22.7%
₿ $QNTM Compra $1M en cripto
🩹 $IONS TRYNGOLZA aprobado FDA
🧑⚕️ $RCEL 510k para Cohealyx
¡Sigue para más!
#Salud #biotech #stocks #mercados
www.biopharmcatalyst.com/news/2024/ap...
FDA approved #Tryngolza (also known as #Olezarsen), an investigational, first-in-class, RNA-targeted medicine for the treatment of adults with familial chylomicronemia syndrome (FCS). FCS is a rare genetic disease that prevents the body from breaking down fats. www.asgct.org/publications...
FDA Approves RNA-targeted Therapy for Familial Chylomicronemia Syndrome
Olezarsen@is the first approved treatment in the U.S. for FCS, which prevents the body from breaking down fats. The treatment is an@antisense oligonucleotide (ASO).
www.asgct.org
December 20, 2024 at 5:05 PM
FDA approved #Tryngolza (also known as #Olezarsen), an investigational, first-in-class, RNA-targeted medicine for the treatment of adults with familial chylomicronemia syndrome (FCS). FCS is a rare genetic disease that prevents the body from breaking down fats. www.asgct.org/publications...
Tryngolza (Olezarsen) | Relatório de avaliação de financiamento público disponível na Infomed | Deferimento do pedido de avaliação prévia
swki.me/oUL1Hm7K
#infarmed #medicamentos #financiamentopublico #tryngolza #olezarsen
swki.me/oUL1Hm7K
#infarmed #medicamentos #financiamentopublico #tryngolza #olezarsen
August 24, 2026 at 7:43 PM
Tryngolza (Olezarsen) | Relatório de avaliação de financiamento público disponível na Infomed | Deferimento do pedido de avaliação prévia
swki.me/oUL1Hm7K
#infarmed #medicamentos #financiamentopublico #tryngolza #olezarsen
swki.me/oUL1Hm7K
#infarmed #medicamentos #financiamentopublico #tryngolza #olezarsen
Olezarsen (Tryngolza) for Severe Hypertriglyceridemia https://medicalletter.org/oleza762c
August 24, 2026 at 1:27 PM
Olezarsen (Tryngolza) for Severe Hypertriglyceridemia https://medicalletter.org/oleza762c
Ionis Q2 Revenue Surpasses Estimates, But Steep TRYNGOLZA Decline Clouds Commercial Outlook https://signalbloom.ai/news/IONS/ionis-q2-revenue-surpasses-estimates-but-steep-tryngolza-decline-clouds-commercial-outlook $IONS #Earnings via @signalbloom.ai
July 29, 2026 at 11:34 AM
Ionis Q2 Revenue Surpasses Estimates, But Steep TRYNGOLZA Decline Clouds Commercial Outlook https://signalbloom.ai/news/IONS/ionis-q2-revenue-surpasses-estimates-but-steep-tryngolza-decline-clouds-commercial-outlook $IONS #Earnings via @signalbloom.ai
Navigating FDA flexibility at the front end and risk at the back end in 2026. Essential read for smaller biotechs and investors:
aktiego.com/market-analy...
#BiotechInvesting #Pharmaceuticals
aktiego.com/market-analy...
#BiotechInvesting #Pharmaceuticals
What the FDA’s Mixed Regulatory Signals in 2026 Mean for Smaller Biotechs - AktieGo
Ionis Tryngolza has a June 30 PDUFA for severe hypertriglyceridemia. Biopharma M&A hit $15.6 billion in Q1. The FDA is more active and more unpredictable than at any point since 2021. Here is what it ...
aktiego.com
June 24, 2026 at 3:48 PM
Navigating FDA flexibility at the front end and risk at the back end in 2026. Essential read for smaller biotechs and investors:
aktiego.com/market-analy...
#BiotechInvesting #Pharmaceuticals
aktiego.com/market-analy...
#BiotechInvesting #Pharmaceuticals
1/ 🧬 #IONS jumped 35% to a 4-year high after its drug Tryngolza (olezarsen) hit Phase III success — lowering triglycerides by ~70% and cutting pancreatitis attacks 85%.
September 3, 2025 at 4:58 PM
1/ 🧬 #IONS jumped 35% to a 4-year high after its drug Tryngolza (olezarsen) hit Phase III success — lowering triglycerides by ~70% and cutting pancreatitis attacks 85%.